Drugmakers and PBMs drive up insulin prices, California says

California has accused Eli Lilly, Sanofi and Novo Nordisk of individually conspiring with major pharmacy benefit managers and abusing their market power to drive up the price of insulin.

Unlock unlimited access to all Global Competition Review content